Tevogen (TVGN) Net Income towards Common Stockholders (2022 - 2026)

Tevogen Bio Holdings (TVGN) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$5.6 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 46.48% year-over-year to -$5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.9 million (up 31.21% YoY) and the FY2025 annual result came in at -$26.8 million, down 161.11% from the prior year.
• Net Income towards Common Stockholders slipped to -$5.6 million in Q1 2026, from -$4.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $56.8 million in Q4 2023 to a low of -$10.5 million in Q1 2025.
• A 5-year average of $608983.4 and a median of -$3.9 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 23461.16% — and 2024, when it plunged 4010.96%.
• Tracing TVGN's Net Income towards Common Stockholders over 5 years: stood at -$243316.0 in 2022, then surged by 23461.16% to $56.8 million in 2023, then slumped by 116.55% to -$9.4 million in 2024, then jumped by 48.8% to -$4.8 million in 2025, then fell by 16.68% to -$5.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$5.6 million (Q1 2026), -$4.8 million (Q4 2025), and -$5.9 million (Q3 2025), per Business Quant data.